Author | Mary-Ellen Taplin, MD | OncLive

Author | Mary-Ellen Taplin, MD

Articles

Dr. Taplin on ARMOR 3-SV Trial for Patients with mCRPC

July 11, 2016

Video

Mary Ellen Taplin, MD, chair, executive committee for Clinical Research, director of Clinical Research, Lank Center for Genitourinary Oncology, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the ongoing ARMOR 3-SV trial for patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Taplin on the Mechanism of Action of Enzalutamide

November 29, 2012

Video

Mary-Ellen Taplin, MD, from the Dana-Farber Cancer Institute, discusses unique mechanism of action of enzalutamide in metastatic castration-resistant prostate cancer.

Dr. Taplin on Abiraterone Acetate's Mechanism of Action

July 17, 2012

Video

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Abiraterone Acetate's Mechanism of Action

Dr. Taplin on Neoadjuvant ADT Plus Hormonal Therapy

June 25, 2012

Video

Dr. Mary-Ellen Taplin, from the Dana-Farber Cancer Institute, on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer.

x